Recombinant erythropoeitins for renal anaemia: risks and rewards

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1566, 2006-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Recombinant erythropoietins for renal anaemia: risks and rewards

Reactions Weekly, Vol. 1, Iss. 1131, 2006-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Recombinant Human Erythropoietin for the Treatment of Renal Anaemia in Children: No Justification for Bodyweight-Adjusted Dosage

By Port R.E.

Clinical Pharmacokinetics, Vol. 43, Iss. 1, 2004-01 ,pp. : 57-70

Adis International

Access to resources Recommend Favorite

Recombinant erythropoietin favoured in chemo-related anaemia

Inpharma, Vol. 1, Iss. 1587, 2007-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Recombinant erythropoietin favoured in chemo-related anaemia

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 527, 2007-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

The Future Costs, Risks and Rewards of Drug Development: The Economics of Pharmacogenomics

By Cook Joseph

PharmacoEconomics, Vol. 27, Iss. 5, 2009-05 ,pp. : 355-363

Adis International

Access to resources Recommend Favorite